Drugs of Abuse Panel, Meconium - Screen with Reflex to Confirmation/Quantitation
Ordering Recommendation
Qualitative Enzyme-Linked Immunosorbent Assay/Quantitative Gas Chromatography-Mass Spectrometry/Quantitative Liquid Chromatography-Tandem Mass Spectrometry
1-4 days  
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
Specimen Required
Patient Preparation
Meconium. All meconium (blackish material) excreted until milk/formula based stool (yellow-green) appears.  
Specimen Preparation
Storage/Transport Temperature
All meconium available (4 g is preferred) at 20-25°C. (Min: 2 g or 3/4 inch cube on each side)  
Unacceptable Conditions
Ambient: 1 week; Refrigerated: 3 months; Frozen: 1 year  
Reference Interval
Drugs Covered and Cutoff Concentrations
Drug Screen Confirmation
Amphetamines 30 ng/g 20 ng/g
Barbiturates 75 ng/g 50 ng/g
Benzodiazepines 75 ng/g 20 ng/g
Buprenorphine 40 ng/g 20 ng/g
Cocaine 30 ng/g 20 ng/g
Marijuana 30 ng/g 5 ng/g
Methadone 40 ng/g 10 ng/g
Opiates 30 ng/g 20 ng/g
Phencyclidine 15 ng/g 10 ng/g
Interpretive Data
Meconium begins to form between the 12th and 16th week of gestation. Meconium drug testing can detect maternal drug use during the last 4 to 5 months of pregnancy. A negative result does not exclude the possibility that a mother used drugs during pregnancy. Detection of drug use depends on the quantity and quality of the specimen tested as well as the pattern and frequency of drug(s) used by the mother. Although not likely, drugs administered during labor and delivery may be detected in meconium. Interpretive questions should be directed to the laboratory.

The concentration at which the screening test can detect a drug or metabolite varies within a drug class. The concentration value must be greater than or equal to the cutoff to be reported as positive.

For medical purposes only; not valid for forensic use.

Compliance Statement B: This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
If the specimen screens positive, then Confirmation/Quantitation by GC/MS and/or LC-MS/MS will be added. Additional charges apply.

Unless ARUP is otherwise notified, reflex confirmation testing will be performed in the following order of priority:

Amphetamines (0.125 g sample required)
Cocaine (0.5 g sample required)
Opiates (0.125 g required)
Buprenorphine (0.125 g required)
Marijuana (0.125 g required)
Benzodiazepines (0.5 g sample required)
Methadone (0.125 g sample required)
Phencyclidine - PCP (0.5 g sample required)
Barbiturates (0.5 g sample required)
CPT Code(s)
80301; if positive, add appropriate CPT code(s): 80326; 80345; 80347; 80349; 80353; 80358; 80364; 80348; 83992; (Alt code: G0431; if positive, add appropriate CPT code(s): G6042; G6031; G6044; G6043; G6053; G6056; 83992; G6056; 82491)
Component Test Code*Component Chart NameLOINC
0092020Marijuana, Meconium8169-5
0092021Cocaine, Meconium40527-4
0092022Opiates, Meconium8216-4
0092023Phencyclidine, Meconium8234-7
0092024Amphetamines, Meconium8146-3
0092318Methadone, Meconium43595-8
0092319Barbiturates, Meconium34578-5
0092517Meconium Comments58738-6
0092518Benzodiazepines, Meconium31081-3
2011913Buprenorphine, Meconium 
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
  • Pain Management